Artbio
Cambridge, United States · Biotechnology · 73 employees
ARTBIO is a clinical-stage radiopharmaceutical company redefining cancer care by creating a new class of alpha radioligand therapies (ARTs). The unique ARTBIO approach selects the optimal alpha-precursor isotope (212Pb) and tumor-specific targets to create therapeutics with the potential for highest efficacy and safety. The company's AlphaDirect™ technology, a first-of-its-kind 212Pb isolation met
Funding history
- Series series b — $132.0M — Jul 2025
- Series series a — $90.0M — Dec 2023
Recent signals
- Jan 06, 2026: ARTBIO Appoints Jonathan Freeman, Ph.D. as Chief Business Officer
- Jul 29, 2025: Raised $132.0M in Series series b
- Jan 10, 2025: Artbio Appoints Margaret Yu as Chief Medical Officer
- Dec 07, 2023: Raised $90.0M in Series series a
- Oct 05, 2023: ARTBIO Announces Appointment of Nick Pullen, Ph.D., as Chief Scientific Officer
See plans & pricing → Track Artbio’s funding, hiring, and signals — with verified contacts — on Fundz.